Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Xevinapant by Ascenta Therapeutics for Gliosarcoma: Likelihood of Approval
Xevinapant is under clinical development by Ascenta Therapeutics and currently in Phase I for Gliosarcoma. According to GlobalData, Phase I...
Xevinapant by Ascenta Therapeutics for Anaplastic Astrocytoma: Likelihood of Approval
Xevinapant is under clinical development by Ascenta Therapeutics and currently in Phase I for Anaplastic Astrocytoma. According to GlobalData, Phase...
Xevinapant by Ascenta Therapeutics for Recurrent Glioblastoma Multiforme (GBM): Likelihood of Approval
Xevinapant is under clinical development by Ascenta Therapeutics and currently in Phase I for Recurrent Glioblastoma Multiforme (GBM). According to...
Xevinapant by Ascenta Therapeutics for High-Grade Glioma: Likelihood of Approval
Xevinapant is under clinical development by Ascenta Therapeutics and currently in Phase I for High-Grade Glioma. According to GlobalData, Phase...
Xevinapant by Merck for Nasopharyngeal Cancer: Likelihood of Approval
Xevinapant is under clinical development by Merck and currently in Phase I for Nasopharyngeal Cancer. According to GlobalData, Phase I...